

## Bluebird bio: summary of recent CAR-T/IO business alliances/deals\$

Company	Partner	Date	Area	Details
bluebirdbio	Novartis AG	2nd May 2017	Non-exclusive licensing of proprietary Lentiviral patent rights	Financial terms of the agreement include an upfront payment to bluebird as well as milestone and royalty payments.
bluebirdbio	Lonza	9 <sup>th</sup> June 2016	Long-term Commercial Manufacturing Agreement for Lenti-D™ and LentiGlobin™ Drug Products	Financial terms not disclosed
bluebirdbio	ViroMed	3 <sup>rd</sup> December 2015	Exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using ViroMed's proprietary humanized antibody	\$1m upfront payment and subsequent milestone payments to ViroMed. Could total over \$48 million per licensed product if certain development and regulatory milestones are achieved. Tiered royalties
bluebirdbio	Kite Pharma	22 <sup>nd</sup> June 2015	Collaboration agreement to co- develop and co-commercialize second generation T cell receptor (TCR) product candidates, HPV*	Both companies will share overall costs, including R&D/sales/ marketing expenses. Profits will be equally split between the companies
*HPV = human papilloma virus			\$ not an exhaus	tive list IO = immuno-oncology





## **About iOnco Analytics:**

iOnco Analytics is a subdivision of VacZine Analytics, a world leading supplier of vaccine market analyses

With our product lines:

- MarketVIEW
- ExpertREACT

Our role is to define market potential and strategy of new cancer immunotherapies

iOnco Analytics is a subdivision of Assay Advantage (VacZine Analytics) Ltd (UK Company No: 5807728, UK VAT: 883584084)

## Disclaimer



## All rights reserved

This licensed product (or part thereof) may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the publisher VacZine Analytics (a division of Assay Advantage Ltd).

The facts presented within this document, at the time of its production, were believed to be correct and were gathered in good faith from both primary and secondary sources. VacZine Analytics is not always in the position to assure that the facts are guaranteed. VacZine Analytics cannot be held liable for any actions based upon facts or recommendations presented within this document.





Immunotherapeutic market strategy...

www.iOnco-analytics.com

Carlton House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
Tel +44 (0) 1279 813155
E-mail: info@ionco-analytics.com